Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074867 | 0.86 | TGM2 (0.55) | GAAPKMTGM2CNR1GPR183 | |
| SCHEMBL4277156 | 0.86 | CNR1 (0.63) | GAAPKMTGM2CNR1GPR183 | |
| SCHEMBL7070017 | 0.83 | DGAT1 (0.50) | GAAPKMTGM2CNR1GPR183 | |
| SCHEMBL10064232 | 0.80 | PKM (0.74) | GAAPKMCNR1MEN1KMT2A | |
| SCHEMBL2953438 | 0.79 | CNR1 (0.65) | TGM2CNR1GPR183MEN1KMT2A | |
| SCHEMBL4265873 | 0.78 | CNR1 (0.64) | TGM2CNR1GPR183MEN1KMT2A | |
| SCHEMBL8898704 | 0.78 | CNR1 (0.67) | TGM2CNR1GPR183MEN1KMT2A | |
| SCHEMBL8564336 | 0.77 | MEN1 (0.83) | TGM2CNR1GPR183MEN1KMT2A | |
| SCHEMBL18702155 | 0.77 | CNR1 (0.62) | TGM2CNR1GPR183MEN1KMT2A | |
| SCHEMBL733443 | 0.77 | GAA (0.70) | GAAPKMMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | GAA 1430/4885PKM 10/4885TGM2 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.